» Articles » PMID: 38016290

Comment on 'Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Versus R0 Resection for Resectable Colorectal Cancer with Peritoneal Metastases and Low Peritoneal Cancer Index Scores: A Collaborative Observational Study from Korea...

Overview
Journal Int J Surg
Specialty General Surgery
Date 2023 Nov 28
PMID 38016290
Authors
Affiliations
Soon will be listed here.
References
1.
Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M . Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2):256-266. DOI: 10.1016/S1470-2045(20)30599-4. View

2.
Ceelen W . HIPEC with oxaliplatin for colorectal peritoneal metastasis: The end of the road?. Eur J Surg Oncol. 2018; 45(3):400-402. DOI: 10.1016/j.ejso.2018.10.542. View

3.
Verwaal V, van Ruth S, de Bree E, van Sloothen G, van Tinteren H, Boot H . Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003; 21(20):3737-43. DOI: 10.1200/JCO.2003.04.187. View

4.
Siegel R, Wagle N, Cercek A, Smith R, Jemal A . Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023; 73(3):233-254. DOI: 10.3322/caac.21772. View

5.
Yuan Z, Xu T, Cai J, Zhao Y, Cao W, Fichera A . Development and Validation of an Image-based Deep Learning Algorithm for Detection of Synchronous Peritoneal Carcinomatosis in Colorectal Cancer. Ann Surg. 2020; 275(4):e645-e651. DOI: 10.1097/SLA.0000000000004229. View